<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ann Transl Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann Transl Med</journal-id>
<journal-id journal-id-type="publisher-id">ATM</journal-id>
<journal-title-group>
<journal-title>Annals of Translational Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">2305-5839</issn>
<issn pub-type="epub">2305-5847</issn>
<publisher>
<publisher-name>AME Publishing Company</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30740403</article-id>
<article-id pub-id-type="pmc">6331355</article-id>
<article-id pub-id-type="publisher-id">atm-06-24-472</article-id>
<article-id pub-id-type="doi">10.21037/atm.2018.12.39</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article on Inborn Errors of Metabolism</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Organic acid disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ramsay</surname>
<given-names>Jessica</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morton</surname>
<given-names>Jacob</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Norris</surname>
<given-names>Marie</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kanungo</surname>
<given-names>Shibani</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><label>1</label>Department of Pediatric and Adolescent Medicine, <institution>Western Michigan University Homer Stryker MD School of Medicine</institution>, <addr-line>Kalamazoo, Michigan</addr-line>, <country>USA</country>;</aff>
<aff id="aff2"><label>2</label>Biochemical Genetics &amp; Nutrition, <institution>Seattle Childrenâ€™s Hospital</institution>, <addr-line>Seattle, Washington</addr-line>, <country>USA</country></aff>
</contrib-group>
<author-notes>
<fn id="afn1">
<p><italic>Contributions</italic>: (I) Conception and design: S Kanungo; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: S Kanungo, M Norris; (IV) Collection and assembly of data: S Kanungo, J Ramsay; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p>
</fn>
<corresp id="cor1"><italic>Correspondence to:</italic> Shibani Kanungo, MD, MPH. Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, 1000 Oakland Drive, Kalamazoo, MI 49008, USA. Email: <email xlink:href="Shibani.Kanungo@med.wmich.edu">Shibani.Kanungo@med.wmich.edu</email>.</corresp>
<fn fn-type="COI-statement">
<p><italic>Conflicts of Interest:</italic> The authors have no conflicts of interest to declare.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2018</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<month>12</month>
<year>2018</year>
</pub-date>
<volume>6</volume>
<issue>24</issue>
<elocation-id>472</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>12</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>2018 Annals of Translational Medicine. All rights reserved.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Annals of Translational Medicine.</copyright-holder>
</permissions>
<abstract>
<p>Organic acids (OAs) are intermediary products of several amino acid catabolism or degradation via multiple biochemical pathways for energy production. Vitamins or co-factors are often quintessential elements in such degradation pathways and OA metabolism. OAs that result from enzyme defects in these pathways can be identified in body fluids utilizing gas chromatography-mass spectrometry techniques (GC/MS). OAs are silent contributor to acid base imbalance and can affect nitrogen balance and recycling. Since OA production occurs in distal steps of a specific amino acid catabolism, offending amino acid accumulation is not characteristic. OA disorders as inborn errors of metabolism (IEM) are included in differential diagnosis of metabolic acidosis, as the common mnemonic MUDPILES taught in medical schools. High anion gap metabolic acidosis with hyperammonemia is a characteristic OA biochemical finding. VOMIT (valine, odd chain fatty acids, methionine, isoleucine, and threonine) is a smart acronym and a common clinical presentation of OA disorders and can present as early life-threatening illness, prior to Newborn Screening results availability. Easy identification and available medical formula make the field of metabolic nutrition vital for management of OA disorders. Treatment strategies also involve cofactor/vitamin utilization to aid specific pathways and disorder management. Optimal metabolic control and regular monitoring is key to long-term management and prevention of morbidity, disability and mortality. Prompt utilization of acute illness protocol (AIP) or emergency protocol and disorder specific education of family members or caregivers, primary care physicians and local emergency health care facilities; cautiously addressing common childhood illnesses in patients with OA disorders, can help avoid poor short- and long-term morbidity, disability and mortality outcomes.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords: </title>
<kwd>Organic acids (OAs)</kwd>
<kwd>valine, odd chain fatty acids, methionine, isoleucine, and threonine (VOMIT)</kwd>
<kwd>high anion gap metabolic acidosis</kwd>
<kwd>hyperammonemia</kwd>
<kwd>neutropenia</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>